TG Therapeutics, Inc. (TGTX) is a New York-based biopharmaceutical company that specializes in developing and commercializing targeted therapies for B-cell malignancies and autoimmune diseases. With a robust pipeline of innovative product candidates, TG Therapeutics leverages advanced drug development technologies to address significant unmet medical needs in oncology and autoimmune treatment. Committed to enhancing patient outcomes through precision medicine and comprehensive clinical programs, the company is positioned to make a substantial impact on treatment paradigms in these critical therapeutic areas. Show more

Location: 3020 CARRINGTON MILL BLVD., MORRISVILLE, NC, UNITED STATES, 27560, Morrisville, NC, 27560, USA | Website: https://www.tgtherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

4.407B

52 Wk Range

$25.28 - $46.48

Previous Close

$27.76

Open

$28.25

Volume

1,622,190

Day Range

$27.83 - $28.95

Enterprise Value

4.529B

Cash

74.08M

Avg Qtr Burn

-23.15M

Insider Ownership

7.23%

Institutional Own.

65.09%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BRIUMVI (ublituximab-xiiy) (CD20) Details Multiple sclerosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BRIUMVI (ublituximab-xiiy) subcutaneous Details Multiple sclerosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azercabtagene zapreleucel (azer-cel) Details Primary progressive multiple sclerosis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TG-1801 Details B-cell malignancies, Cancer, B-cell lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TG-1701 (BTK inhibitor) Details Chronic lymphocytic leukemia, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Umbralisib (PI3K-delta & CK1-epsilon inhibitor) + Ublituximab (CD20) Details R/R CLL (Relapsed/Refractory Chronic Lymphocytic Leukemia)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
UKONIQ® (Umbralisib) (PI3K-delta & CK1-epsilon inhibitor) Details FL (Follicular Lymphoma)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.